Skip to Main Content

A version of this story appeared in STAT’s biotech newsletter, The Readout. Sign up here.

Regeneron Pharmaceuticals yesterday announced it would spend $1 billion buying its own stock, a move that was both unremarkable and remarkable at the same time.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!